A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia.

Ingrezza (valbenazine) - Neurocrine

(+)-α-dihydrotetrabenazine (ADE 513) - Adeptio Pharma

http://www.ncbi.nlm.nih.gov/pubmed/39051716

Gordon Loewen; Han-Yi Steve Kuan; Hoa Q Nguyen; Kristine Kim; Lauren Quinlan; Ryan L Crass; Satjit Brar; Sunny Chapel

Jul 27, 2024